ADSCC performs first CAR-T Cell therapy to treat Lupus in the Middle East

In a groundbreaking achievement, the Abu Dhabi Stem Cells Center (ADSCC) has performed the Middle East's first Chimeric Antigen Receptor T-Cell (CAR-T) therapy to treat systemic lupus erythematosus (SLE). This pioneering step marks a transformative moment in the personalized treatment of autoimmune diseases.

By utilizing genetically engineered immune cells, ADSCC offers renewed hope for patients battling the debilitating effects of lupus, a disease that causes the immune system to attack healthy tissues.

How does it work?

CAR-T therapy leverages the body's immune system to combat diseases by genetically modifying T-cells to target and destroy harmful cells. In the case of lupus, this revolutionary treatment reprograms immune cells to stop attacking the body's own tissues. The five-week therapy performed at Yas Clinic, part of the FACT-accredited ADSCC, demonstrated remarkable results. Clinical trials revealed that patients with severe, treatment-resistant lupus achieved complete remission, remaining symptom-free for years without additional medication.

The patient's recovery included stabilized platelet counts and improved hemoglobin levels within just three months, showcasing the therapy's potential to deliver sustained remission.

Why does it matter?

This milestone holds immense significance for the medical community and patients alike. Lupus affects 43.7 per 100,000 people globally, with a notable prevalence in the Middle East. Traditional treatments often fall short, leaving approximately 10% of lupus patients suffering from persistent flares and severe complications. CAR-T therapy offers a groundbreaking solution, enabling drug-free remission and significantly improving quality of life.

"Our success in treating lupus here in Abu Dhabi is a major milestone," remarked Prof. Yendry Ventura, CEO of ADSCC. "Guided by the UAE's leadership, we are advancing cancer and autoimmune treatments using genetically modified immune cells, delivering life-changing care."

This breakthrough alleviates the suffering of lupus patients and strengthens the UAE's position as a global leader in medical innovation.

The context

Lupus is a chronic autoimmune condition that leads to inflammation, pain, and damage to various organs, including the skin, joints, lungs, and kidneys. Despite advancements in pharmaceuticals, many patients face ongoing challenges, such as active flares and organ damage. The introduction of CAR-T therapy represents a paradigm shift in treatment options, providing hope for those who have exhausted traditional therapies.

Dr. Fatima Al Kaabi, Executive Director of the Abu Dhabi Bone Marrow Transplant Programme at ADSCC, highlighted the broader implications: "This achievement strengthens the UAE's position as a global leader in medical innovation and reflects the relentless efforts of our multidisciplinary team. We are proud to see the patient return to normal life, free from immunosuppressant medications."

By offering cutting-edge treatments like CAR-T therapy locally, ADSCC eliminates the need for patients to travel abroad, making life-changing care accessible to the region.